Sebacia

Sebacia, Inc. is a U.S. private, commercial-stage dermatology and aesthetics company focused on advancing a novel FDA-cleared procedure-based treatment for acne treatment called Sebacia Microparticles.

Sebacia’s goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne.

Sebacia’s microparticles technology was invented and licensed from Rice University, and the dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital.

The U.S. Food and Drug Administration (FDA) granted clearance for Sebacia Microparticle for the treatment of mild to moderate acne and follows the company’s completion of its U.S. pivotal study, which clearly demonstrated clinical efficacy and safety of Sebacia Microparticles.

Sebacia’s advanced, patented technology combines gold microparticles and existing dermatology lasers and represents the newest innovation in acne in two decades. Sebacia Microparticles are designed to selectively and locally heat the oil-producing (sebaceous) glands – a root cause of acne lesions – to reduce their size and oil-producing activity.

Learn more about Sebacia Microparticles and our next steps for commercializing in the U.S. by visiting www.sebacia.com

Sebacia is located in Duluth, Georgia.

Company’s Keywords:

dermatology, microparticles, medical device, acne treatment, aesthetics